Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The ever-increasing use of immune checkpoint inhibitors in cancer is leading to a high incidence of autoimmune side effects. This report discusses an autoimmune fulminant myocarditis in an elderly patient with metastatic pulmonary adenocarcinoma in whom the most advanced invasive heart failure therapies were used successfully. She was treated with nivolumab. This case illustrates a severe cardiovascular complication of immunotherapy and highlights to cardiologists the importance of aggressive treatments in patients with metastatic cancers whose prognosis has improved dramatically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288 · cited 1×
“The mechanism of this cardiotoxicity is likely related to the role of PD-1 in cardiomyocyte protection against autoimmune attacks, because PD-1edeficient mice develop dilated cardiomyopathy.(2) As shown for other irAEs,(3) rapid diagnosis appears critical to downsize the immune attack using steroid therapy.”
Background
Cited by
Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271
Palaskas, N., Lopez‐Mattei, J., Durand, J. B., Iliescu, C., & Deswal, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013757 · Cited by 535
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 485
Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
Zotova, L. (2023) · Diagnostics · doi:10.3390/diagnostics13071243 · Cited by 64
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
“…treatment of ICI-related myocarditis with various agents, including intravenous immunoglobulin (160), mycophenolate (161), in fl iximab (anti-TNF mAb) (162), anti – thymocyte globulin (145), plasmapheresis (162), alemtuzumab (anti-CD52 mAb) (163), and abatacept (CTLA-4 agonistic mAb) (164).”
Background
Metadata
- Authors
- Frigeri, M., Meyer, P., Banfi, C., Giraud, R., Hachulla, A.-L., Spoerl, D., Friedlaender, A., Pugliesi-Rinaldi, A., & Dietrich, P.-Y.
- Venue
- Canadian Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 34
- Issue
- 1
- Pages
- 92.e1-92.e3
- ISSN
- 0828-282X (ISSN-L)
- OpenAlex
- W2766602219
- Cited by
- 95
- References
- 4
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. https://app.cochat.ai/papers/10.1016/j.cjca.2017.09.025
- The paper
- Frigeri, M., Meyer, P., Banfi, C., Giraud, R., Hachulla, A.-L., Spoerl, D., Friedlaender, A., Pugliesi-Rinaldi, A., & Dietrich, P.-Y. (2018). Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2017.09.025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.